Why Did Cathie Wood Buy AMD?
Noted tech investor Cathie Wood has used the recent stock…
Buy
58
KRYS Quote, Financials, Valuation and Earnings
Last price:
$166.08
Seasonality move
:
23.5%
Day range:
$165.53 - $169.31
52-week range:
$141.72 - $219.34
Dividend yield:
0%
P/E ratio:
55.57x
P/S ratio:
16.98x
P/B ratio:
5.07x
Volume:
228.2K
Avg. volume:
304.4K
1-year change:
3.7%
Market cap:
$4.8B
Revenue:
$290.5M
EPS (TTM):
$2.99
Analysts' Opinion
-
Consensus RatingKrystal Biotech has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $217.20, Krystal Biotech has an estimated upside of 30.72% from its current price of $166.16.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $195.00 representing 100% downside risk from its current price of $166.16.
Fair Value
-
According to the consensus of 9 analysts, Krystal Biotech has 30.72% upside to fair value with a price target of $217.20 per share.
KRYS vs. S&P 500
-
Over the past 5 trading days, Krystal Biotech has underperformed the S&P 500 by -3.94% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Krystal Biotech does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Krystal Biotech has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Krystal Biotech reported revenues of $91.1M.
Earnings Growth
-
Krystal Biotech has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Krystal Biotech reported earnings per share of $1.52.
Enterprise value:
4.2B
EV / Invested capital:
--
Price / LTM sales:
16.98x
EV / EBIT:
40.74x
EV / Revenue:
14.47x
PEG ratio (5yr expected):
--
EV / Free cash flow:
35.28x
Price / Operating cash flow:
41.40x
Enterprise value / EBITDA:
38.25x
Gross Profit (TTM):
$270.5M
Return On Assets:
9.63%
Net Income Margin (TTM):
30.69%
Return On Equity:
10.49%
Return On Invested Capital:
10.49%
Operating Margin:
45.4%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | $290.5M | $42.1M | $91.1M | |
| Gross Profit | -- | $47.6M | $270.5M | $39.3M | $86.2M | |
| Operating Income | -$120.2M | -$97.2M | $103.2M | $3.1M | $41.4M | |
| EBITDA | -$116.8M | -$91.3M | $109.9M | $4.9M | $42.9M | |
| Diluted EPS | -$5.51 | $0.09 | $2.99 | $0.31 | $1.52 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $275.1M | $442.3M | $383.8M | $587.9M | $742M | |
| Total Assets | $310.8M | $626.3M | $558.5M | $818.4M | $1.1B | |
| Current Liabilities | $15.5M | $25.7M | $28.8M | $33.1M | $102M | |
| Total Liabilities | $18.8M | $32.7M | $36.2M | $39.7M | $109.5M | |
| Total Equity | $292.1M | $593.6M | $522.2M | $778.6M | $946.4M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$100.6M | -$88.8M | $123.4M | -$7.2M | $52.8M | |
| Cash From Investing | -$114.1M | $82.6M | -$163.4M | -$10.2M | -$83.8M | |
| Cash From Financing | $35.3M | $202.8M | $27M | $2.6M | $2.4M | |
| Free Cash Flow | -$153.5M | -$100.6M | $119.2M | -$9.1M | $52M | |
KRYS
Sector
Market Cap
$4.8B
$35.8M
Price % of 52-Week High
75.76%
45.38%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.81%
1-Year Price Total Return
3.7%
-38.89%
Beta (5-Year)
0.787
0.662
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$168.13
200-day SMA
Sell
Level
$178.05
Bollinger Bands (100)
Sell
Level
155.64 - 180.66
Chaikin Money Flow
Buy
Level
2M
20-day SMA
Sell
Level
$166.84
Relative Strength Index (RSI14)
Sell
Level
45.45
ADX Line
Sell
Level
20.02
Williams %R
Neutral
Level
-67.3248
50-day SMA
Sell
Level
$175.91
MACD (12, 26)
Sell
Level
-1.95
25-day Aroon Oscillator
Sell
Level
-32
On Balance Volume
Neutral
Level
29M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (25.8121)
Buy
CA Score
(Annual)
Level (2.0827)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (7)
Buy
Ohlson Score
Level (-4.9943)
--
Piotroski F Score
(Annual)
Level (--)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
Stock Forecast FAQ
In the current month, KRYS has received 8 Buy ratings 1 Hold ratings, and 0 Sell ratings. The KRYS average analyst price target in the past 3 months is $217.20.
-
Where Will Krystal Biotech Stock Be In 1 Year?
According to analysts, the consensus estimate is that Krystal Biotech share price will rise to $217.20 per share over the next 12 months.
-
What Do Analysts Say About Krystal Biotech?
Analysts are divided on their view about Krystal Biotech share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Krystal Biotech is a Sell and believe this share price will drop from its current level to $195.00.
-
What Is Krystal Biotech's Price Target?
The price target for Krystal Biotech over the next 1-year time period is forecast to be $217.20 according to 9 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is KRYS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Krystal Biotech is a Buy. 8 of 9 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of KRYS?
You can purchase shares of Krystal Biotech via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Krystal Biotech shares.
-
What Is The Krystal Biotech Share Price Today?
Krystal Biotech was last trading at $166.08 per share. This represents the most recent stock quote for Krystal Biotech. Yesterday, Krystal Biotech closed at $166.16 per share.
-
How To Buy Krystal Biotech Stock Online?
In order to purchase Krystal Biotech stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Salesforce Stock Drop After a Strong Quarter?
Popular customer relationship management platform provider Salesforce (NYSE:CRM) has been…
Is Adobe Stock a Bargain With AI Tools Driving Growth?
The share price of American computer software company Adobe (NASDAQ:ADBE)…
Stock Ideas
Buy
71
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Buy
63
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Sell
4
CABO alert for May 3
Cable One [CABO] is down 41.98% over the past day.
Buy
55
PDEX alert for May 3
Pro-Dex [PDEX] is down 32.02% over the past day.
Buy
91
TRUP alert for May 3
Trupanion [TRUP] is up 23.52% over the past day.
